Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern cART era.
Fiche publication
Date publication
septembre 2017
Journal
AIDS (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier
Tous les auteurs :
Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekerri N, Dos Santos G, Recher C, Delarue R, Casasnovas RO, Taoufik Y, Mounier N, Costagliola D,
Lien Pubmed
Résumé
Non-Hodgkin's lymphoma (NHL) remains among the most frequent malignancies in persons living with HIV (PLWHIV). Survival among patients with HIV-associated diffuse large B-cell lymphoma (DLBCL), the most frequent NHL subtype, has improved markedly in recent years. We aimed to analyze characteristics and outcomes of DLBCL in HIV-infected patients in the era of modern combined antiretroviral therapy (cART).
Mots clés
Adolescent, Adult, Aged, Aged, 80 and over, Anti-Retroviral Agents, therapeutic use, Antineoplastic Agents, therapeutic use, Female, France, HIV Infections, complications, Humans, Lymphoma, Large B-Cell, Diffuse, drug therapy, Male, Middle Aged, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult
Référence
AIDS. 2017 Sep;: